Ablynx secures FDA approval for Cablivi to treat aTTP
In a significant milestone for Belgian biopharma company Ablynx, the U.S. Food and Drug Administration (FDA) has granted approval for Cablivi (caplacizumab-yhdp), a nanobody designed to treat acquired thrombotic thrombocytopenic purpura (aTTP). The FDA’s decision enables the drug to be used in combination with plasma exchange and immunosuppressive therapy, providing a much-needed treatment option for […]